Financial toxicity in cancer remains a significant barrier to optimal patient outcomes. A recent cross-sectional study highlights how economic strain directly correlates with healthcare disruptions among working-age cancer survivors. By analyzing data from 309 survivors aged 27 to 64, researchers identified a clear link between financial stress and missed medical care. Consequently, understanding these dynamics is crucial for oncology teams striving to maintain care continuity during and after economic crises.

The study researchers employed the COmprehensive Score for financial Toxicity (COST) instrument to evaluate perceived distress. They categorized participants into mild, moderate, and severe toxicity levels based on their responses. Additionally, the team tracked material financial stressors like medical debt and depleted savings. Findings revealed that 46.6% of survivors experienced at least one healthcare disruption since the start of the COVID-19 pandemic. Specifically, these disruptions included delayed follow-up visits and skipped medications.

Addressing Financial Toxicity in Cancer Care

The association between financial burden and access to care is profound. Specifically, survivors reporting severe perceived financial toxicity were nearly twice as likely to experience disruptions compared to those with lower stress levels. For instance, 49.3% of those with healthcare disruptions reported severe toxicity, while only 24.8% of those without disruptions felt the same. Moreover, material financial stressors served as independent predictors for treatment delays. Therefore, clinicians must look beyond clinical symptoms to understand the economic reality of their patients.

Early identification of financial risk can prevent long-term healthcare abandonment. Providers should integrate validated tools like the COST instrument into routine clinical assessments. Furthermore, multidisciplinary teams can help patients navigate insurance complexities and access support programs. By fostering open communication about treatment costs, physicians can improve adherence and patient trust. Ultimately, mitigating financial toxicity in cancer is a vital component of holistic patient care and survivorship management.

Frequently Asked Questions

How is financial toxicity in cancer measured?

Healthcare providers often use the COmprehensive Score for financial Toxicity (COST) instrument. This 11-item questionnaire assesses a patient's financial well-being, including their ability to pay for treatment and the psychological distress associated with costs.

What are common signs of healthcare disruptions?

Healthcare disruptions often manifest as missed oncology appointments, delayed diagnostic imaging, or the non-adherence to prescribed medications. These issues frequently stem from financial toxicity, as patients prioritize immediate living expenses over medical care.

Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Korgaonkar S et al. Financial toxicity and healthcare disruptions among working-age cancer survivors in the United States: Insights from the COVID-19 pandemic and future challenges. Psychol Health Med. 2026 Apr 19. doi: 10.1080/13548506.2026.2659693. PMID: 42001501.

2. Zafar SY. Financial toxicity: the new side-effect of cancer treatment. Nat Rev Clin Oncol. 2013;10(5):250-251.

3. Ramaswamy A, et al. Prevalence and impact of financial toxicity in older patients with cancer: a prospective observational study in India. Support Care Cancer. 2025.